Alliance Pharma PLC Preliminary Results -3-
March 25 2015 - 3:01AM
UK Regulatory
Consolidated Income Statement
Year Year
ended ended
31 December 31 December
2014 2013
Note Restated*
GBP 000s GBP 000s
------------------------------------- ---- ------------ ---------------------
Revenue 43,536 45,275
Cost of sales (18,493) (17,944)
------------------------------------- ---- ------------ ---------------------
Gross profit 25,043 27,331
------------------------------------- ---- ------------ ---------------------
Operating expenses
Administration and marketing expense (12,510) (12,917)
Amortisation of intangible assets (488) (422)
Share-based employee remuneration (571) (632)
Share of joint venture profits
/ (losses) 319 (48)
------------------------------------- ---- ------------ ---------------------
(13,250) (14,019)
------------------------------------- ---- ------------ ---------------------
Operating profit excluding exception
item
11,793 13,312
Exceptional item: impairment of
intangible asset (622) -
------------------------------------- ---- ------------ ---------------------
Operating profit 11,171 13,312
Finance costs
Interest payable and similar charges 2 (1,090) (1,281)
Interest income 2 48 50
Other finance income / (charges) 2 28 (72)
(1,014) (1,303)
------------------------------------- ---- ------------ ---------------------
Profit on ordinary activities
before taxation 10,157 12,009
Taxation 3 (1,772) (2,425)
------------------------------------- ---- ------------ ---------------------
Profit for the year attributable
to equity shareholders 8,385 9,584
------------------------------------- ---- ------------ ---------------------
Earnings per share
Basic (pence) 5 3.17 3.82
Diluted (pence) 5 3.16 3.68
------------------------------------- ---- ------------ ---------------------
*Restated due to the adoption of IFRS 11, please see note
11.
Consolidated Statement of Comprehensive Income
Year ended Year ended
31 December 31 December
2014 2013
GBP 000s GBP 000s
Profit for the period 8,385 9,584
Other comprehensive income
Other items recognised directly
in equity
Items that may be reclassified
to profit or loss
Interest rate swaps - cash flow
hedge (572) 443
Deferred tax on interest rate
swaps 119 (93)
Foreign exchange translation 7 -
differences
Share of joint venture OCI (8) -
Total comprehensive income for
the period 7,931 9,934
------------------------------------- ------------- -------------
Consolidated Statement of Financial Position
31 December 31 December 31 December 31 December
2014 2014 2013 2013
Restated* Restated*
Note GBP 000s GBP 000s GBP 000s GBP 000s
----------------------------- ---- ----------- ----------- ----------- -----------
Assets
Non-current assets
Intangible assets 6 88,875 87,111
Property, plant and
equipment 396 592
Joint Venture Investment 1,271 533
Joint Venture Receivable 1,462 1,462
Derivative financial
instruments - 443
Deferred tax asset 194 -
92,198 90,141
Current assets
Inventories 5,914 5,468
Trade and other receivables 7 8,322 10,641
Cash and cash equivalents 10 1,434 687
15,670 16,796
Total assets 107,868 106,937
----------------------------- ---- ----------- ----------- ----------- -----------
Equity
Ordinary share capital 2,641 2,641
Share premium account 29,388 29,380
Share option reserve 1,995 1,424
Reverse takeover reserve (329) (329)
Other reserve (103) 350
Retained earnings 37,188 31,202
----------------------------- ---- ----------- ----------- ----------- -----------
Total equity 70,780 64,668
Liabilities
Non-current liabilities
Long term financial
liabilities 19,235 20,881
Deferred tax liability 6,309 6,294
Provisions for other
liabilities - 199
Derivative financial
instruments 129 -
----------------------------- ---- ----------- ----------- ----------- -----------
25,673 27,374
Current liabilities
Cash and cash equivalents 10 414 2,125
Financial liabilities 2,895 2,895
Corporation tax 959 1,154
Trade and other payables 8 6,920 8,531
Provisions for other
liabilities 227 190
11,415 14,895
Total liabilities 37,088 42,269
Total equity and liabilities 107,868 106,937
----------------------------- ---- ----------- ----------- ----------- -----------
*Restated due to the adoption of IFRS 11, please see note 11
Consolidated Statement of Changes in Equity
Ordinary Share Share Reverse
share premium option takeover Other Retained Total
capital account reserve reserve reserve earnings equity
GBP
GBP 000s GBP 000s GBP 000s GBP 000s GBP 000s GBP 000s 000s
Balance 1 January
2014 2,641 29,380 1,424 (329) 350 31,202 64,668
-------------------------- --------- --------- --------- ---------- --------- ---------- --------
Issue of shares - 8 - - - - 8
Dividend paid - - - - - (2,398) (2,398)
Share options charge - - 571 - - - 571
-------------------------- --------- --------- --------- ---------- --------- ---------- --------
Transactions with
owners - 8 571 - - (2,398) (1,819)
-------------------------- --------- --------- --------- ---------- --------- ---------- --------
Profit for the period - - - - - 8,385 8,385
Other comprehensive
income
Interest rate swaps
- cash flow hedge - - - - (572) - (572)
Deferred tax on interest
rate swap - - - - 119 - 119
Foreign exchange
translation differences - - - - - (1) (1)
-------------------------- --------- --------- --------- ---------- --------- ---------- --------
Total comprehensive
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024